MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
Mannkind Corporation (NASDAQ: MNKD) Delayed: 3.93 +0.04 (1.03%)
Previous Close $3.89    52 Week High $2.51 
Open $3.86    52 Week Low $0.41 
Day High $3.94    P/E N/A 
Day Low $3.85    EPS $-0.64 
Volume 2,985,898       

Mannkind Corporation (NASDAQ: MNKD) Delayed: 3.93 +0.04 (1.03%)
Previous Close $3.89    52 Week High $2.51 
Open $3.86    52 Week Low $0.41 
Day High $3.94    P/E N/A 
Day Low $3.85    EPS $-0.64 
Volume 2,985,898